Insider Selling: Axon Enterprise, Inc. (NASDAQ:AXON) CEO Sells $1,926,535.38 in Stock

by · The Cerbat Gem

Axon Enterprise, Inc. (NASDAQ:AXON – Get Free Report) CEO Patrick W. Smith sold 4,767 shares of the business’s stock in a transaction dated Thursday, October 3rd. The shares were sold at an average price of $404.14, for a total value of $1,926,535.38. Following the completion of the transaction, the chief executive officer now owns 2,925,060 shares in the company, valued at $1,182,133,748.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Axon Enterprise Price Performance

Shares of AXON opened at $421.80 on Monday. The company has a 50 day moving average of $365.66 and a two-hundred day moving average of $323.62. The company has a quick ratio of 2.52, a current ratio of 2.88 and a debt-to-equity ratio of 0.35. Axon Enterprise, Inc. has a twelve month low of $192.63 and a twelve month high of $422.33. The company has a market cap of $31.83 billion, a price-to-earnings ratio of 123.33, a price-to-earnings-growth ratio of 10.84 and a beta of 0.94.

Axon Enterprise (NASDAQ:AXON – Get Free Report) last issued its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.18. The firm had revenue of $504.00 million for the quarter, compared to analyst estimates of $478.35 million. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. Axon Enterprise’s revenue for the quarter was up 34.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.80 earnings per share. As a group, analysts predict that Axon Enterprise, Inc. will post 1.79 earnings per share for the current fiscal year.

Institutional Trading of Axon Enterprise

Hedge funds have recently modified their holdings of the stock. Avantax Advisory Services Inc. boosted its position in Axon Enterprise by 0.8% in the 1st quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock worth $1,659,000 after purchasing an additional 40 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in Axon Enterprise during the first quarter worth $931,000. Sumitomo Mitsui Trust Holdings Inc. grew its position in Axon Enterprise by 14.8% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 170,376 shares of the biotechnology company’s stock valued at $53,307,000 after buying an additional 22,013 shares during the period. Wealth Enhancement Advisory Services LLC increased its holdings in Axon Enterprise by 21.7% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 9,153 shares of the biotechnology company’s stock valued at $2,693,000 after buying an additional 1,634 shares in the last quarter. Finally, Cim LLC acquired a new position in shares of Axon Enterprise in the fourth quarter worth about $1,409,000. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on AXON. Bank of America started coverage on Axon Enterprise in a report on Wednesday, July 17th. They issued a “buy” rating and a $380.00 price target on the stock. Barclays upped their target price on shares of Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Jefferies Financial Group initiated coverage on Axon Enterprise in a report on Wednesday, July 17th. They issued a “buy” rating and a $385.00 target price on the stock. JMP Securities upped their price target on shares of Axon Enterprise from $375.00 to $430.00 and gave the company an “outperform” rating in a research note on Thursday, September 12th. Finally, Northland Securities raised their price objective on Axon Enterprise from $330.00 to $365.00 and gave the company an “outperform” rating in a research note on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Axon Enterprise has a consensus rating of “Moderate Buy” and an average target price of $365.38.

View Our Latest Stock Report on Axon Enterprise

About Axon Enterprise

(Get Free Report)

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

Featured Articles